文献速递胸部肿瘤

广泛期小细胞肺癌:一线与二线治疗选择

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.
PubMed 文献 · J Clin Oncol · 2022-01-05

广泛期小细胞肺癌治疗困难,在铂类化疗基础上加入程序性细胞死亡蛋白1轴阻断已显示持续总生存获益,成为当前一线标准治疗,但几乎所有患者仍较快出现耐药。复发患者治疗耐药明显,亟需更有效疗法;分子生物学进展可能带来分子指导的治疗策略。本文综述一线及复发小细胞肺癌的当前治疗选择与近期进展,包括生物标志物作用及新治疗策略。

要点

  • 铂类化疗联合程序性细胞死亡蛋白1轴阻断是广泛期小细胞肺癌当前一线标准治疗,具持续总生存获益。
  • 尽管一线获益,几乎所有患者仍较快出现耐药。
  • 复发小细胞肺癌治疗耐药明显,亟需开发更有效疗法。

核心结论

  • 铂类化疗联合程序性细胞死亡蛋白1轴阻断是广泛期小细胞肺癌当前一线标准治疗,具持续总生存获益,但几乎所有患者仍较快出现耐药。
  • 复发小细胞肺癌治疗耐药明显,亟需开发更有效疗法;分子生物学进展可能带来分子指导的治疗策略。

研究设计与样本

  • 综述,回顾当前一线及复发小细胞肺癌的治疗选择与近期进展,包括生物标志物作用及新治疗策略。

主要发现

  • 在铂类化疗基础上加入程序性细胞死亡蛋白1轴阻断已显示持续总生存获益。
  • 尽管一线治疗有获益,几乎所有患者仍较快出现耐药。
  • 复发小细胞肺癌中通常观察到明显治疗耐药。
  • 分子生物学认识进展可能为小细胞肺癌患者带来分子指导的治疗策略。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Extensive-stage small-cell lung cancer is a therapeutically challenging disease. After more than two decades without clinical progress, the addition of programmed cell death protein 1 axis blockade to platinum-based chemotherapy has demonstrated sustained overall survival benefit and represents the current standard of care in the first-line setting. Despite this benefit, resistance emerges relatively rapidly in virtually all patients. Although newer treatments are being incorporated in the relapse setting, marked therapeutic resistance is typically observed in patients with relapsed small-cell lung cancer (SCLC), underscoring the need of developing more effective therapies in this setting. Notably, recent progress in the understanding of the molecular biology of SCLC might bring possibilities toward molecularly informed therapeutic strategies for patients with SCLC, which could have a significant impact for improving outcomes in this disease. Here, we review current treatment options and recent progress made in the first-line and relapsed SCLC, including the role of biomarkers and new evolving therapeutic strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Zugazagoitia J, Paz-Ares L. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022. PMID: 34985925. doi:10.1200/JCO.21.01881

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。